All In Biotech

NDA 022485 · Plano Pharms

Argatroban In Sodium Chloride

Argatroban · Intravenous · Anti-coagulant; Direct Thrombin Inhibitor

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

May 9, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

32

5 Phase 3, 1 recruiting

FAERS reports

1,499

1,309 serious, 321 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2026.

1 Argatroban in 0.9% Sodium Chloride Injection is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) ( 1.1 ) As an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI) ( 1.2 ) 1.1 Heparin-Induced Thrombocytopenia Argatroban in 0.9% Sodium Chloride Injection is indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT). 1.2 Percutaneous Coronary Intervention Argatroban in 0.9% Sodium Chloride Injection is indicated as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI).

Mechanism: Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation. Argatroban inhibits thrombin with an inhibition constant (Ki) of 0.04 μM. At therapeutic concentrations, argatroban has little or no effect on related serine proteases (trypsin, factor...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ARGATROBAN IN SODIUM CHLORIDE · ARGATROBAN 125MG/125ML (1MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Argatroban" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heparin-induced thrombocytopenia191
  • drug ineffective157
  • international normalised ratio increased110
  • off label use99
  • activated partial thromboplastin time prolonged83
  • haemorrhage81
  • pulmonary embolism70
  • thrombocytopenia70
  • deep vein thrombosis69
  • coagulation time prolonged64
  • thrombosis56
  • gastrointestinal haemorrhage54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200522
200642
200764
200848
200947
2010195
201199
201274
201339
201443
201547
201632
201768
201853
201987
202086
202194
202292
202369
202461
202583
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 116 on PubMed

Sponsor: Plano Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.